New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Psyence Biomedical Ltd.

PBM

Healthcare Biotechnology

2.97 0.11 +3.85%

After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.

Market cap
$10.9M
P/E
0.1×
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
1.2×
Payout ratio
—

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '23 Jun '23 Mar '23 Dec '22 Older periods
Non-operating Income/Expense
(0.79) (0.78) (2.74) (5.76)

+4 more TTM periods

Non-operating Interest Expenses
3.33 4.10 4.03 3.55
EBT
1.85 2.93 5.04 8.01
Net Income Common
1.85 2.93 5.04 8.01
EPS (Basic)
(0.02) 0.09 0.17 0.27
EPS (Diluted)
(0.02) 0.09 0.17 0.27
Shares (Basic, Weighted)
14.96 20.17 25.29 29.57
Shares (Diluted, Weighted)
14.96 20.17 25.29 29.57
EBITDA
(1.97) (1.96) (1.74) (1.29)
Other line items
SG&A Expenses
1.78 1.96 1.74 1.29
Consolidated Net Income/Loss
1.85 2.93 5.04 8.01

Fold the line items

In millions of $ except per-share values · columns are period end dates